Good morning to everyone, and thank you for joining us this morning. Thank you all for standing by, and I'd like to take this opportunity to welcome you all to the I-Mab Biopharma full year 2022 financial results and business update conference call. This is Tyler Ehler here, I-Mab Senior Director of Investor Relations.
At this time, all participants are in a listen-only mode. At the end of this call, we'll conduct a Q&A session, and instructions will follow at that time. Earlier today, we issued a press release providing a review of our financial results for the full year ended December 31, 2022, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investor Relations tab on our website at ir.i-mabbiopharma.com. Joining me today on the call from I-Mab senior management team are Dr. Jingwu Zang, our founder and chairman; Dr. Andrew Zhu, our acting CEO; and Mr. Richard Yeh, our interim CFO and COO.
To start, Dr. Andrew Zhu will provide a high-level overview of our recent achievements and upcoming milestones. He'll also provide an update on our R&D progress. Mr. Yeh will then provide a summary of our financial results for the full year ended December 31, 2022, before we turn the call over to the operator to take your questions. Please note that today's discussion will contain forward-looking statements relating to the company's future performance and are made under the Safe Harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions, as well as other factors.
Some of these risks are beyond the company's control and could cause actual results to differ materially from those mentioned in today's press release and in today's discussion. A general discussion of the risk factors that could affect I-Mab's business and financial results is included in certain filings of the company of the Securities and Exchange Commission. The company does not undertake any obligation to update this forward-looking information except as required by law.
We also discuss specific non-GAAP financial measures during today's call, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. Please see the financial results press release issued today for a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial results. With that, I'll now turn the call over to Dr. Andrew Zhu, our Acting CEO. Dr. Zhu, please go ahead.
Thank you, Tyler. It's a pleasure to welcome all of you to our call today. I want to take this opportunity to discuss our key business update and major progress in core asset development for the year ended December 31, 2022. Since the start of 2022, the company faced multiple challenges, including, but not limited to geopolitical issues such as ADR delisting risk, macroeconomic factors, including interest rate hikes and COVID-19 pandemic.
In response to these challenges, the company made several strategic efforts to reposition the overall business and prioritize its pipeline. These measures resulted in a streamlined corporate structure and workforce, as well as focused development of five key assets, leading to a significant reduction in the cash burn rate in 2022 and beyond. These efforts have allowed us to achieve critical milestones for our prioritized pipeline and deliver near-term value.
In terms of the ADR delisting risk, on December 15, 2022, the PCAOB issued a report that vacated the previous determination and removed Mainland China and Hong Kong from the list of jurisdiction where it is unable to inspect or investigate completely registered public accounting firms. For this reason, the company does not expect to be identified as a commission-identified issuer under the HFCAA after it files the annual report on Form 20-F for the fiscal year 2022.
This has removed a significant headwind the company faced in 2022. With the above-mentioned strategic efforts on the pipeline develop front in 2022, we achieved 13 key clinical milestones, including positive results, including positive data readouts for three of our key assets, lemzoparlimab, uliledlimab, and givastomig. Here, we highlight the five key clinical assets that we have prioritized.
These assets are novel, highly differentiated, and among the front runners globally and all in China. First of all, eftansomatropin alfa, our long-acting growth hormone. We completed the enrollment of 168 patients for our phase III trial in the first half of 2022. We expect to have a data readout in the second half of 2023, followed by subsequent BLA submission.
In November 2021, we announced a commercial partnership with Jumpcan, a top 100 Chinese pharmaceutical company specialized in the pediatric space. Second, felzartamab, a differentiated CD38 antibody. In addition to the completed phase II registration study, our phase III study for second-line multiple myeloma is on track despite the impact of COVID-19. Continue to make progress with the local manufacturing plan in preparation for BLA submission and seek a potential commercial partnership.
Next, we have three key assets that I will discuss in more detail later. lemzoparlimab, a differentiated CD47 antibody, has reached the phase III stage. uliledlimab, a differentiated CD73 antibody and a global front-runner, has demonstrated impressive antitumor activity in non-small cell lung cancer in a phase II trial.
The clinical response is correlated with tumor CD73 expression. Next, givastomig, a Claudin 18.2/ 4-1BB bispecific antibody with a favorable safety profile and single-agent efficacy signal. I would like to start by highlighting our highly differentiated CD47 antibody, lemzoparlimab, which has certainly attracted so much attention in the immuno-oncology field because of its leading position to be among the first CD47 antibody drugs potentially approved for hematological malignancies.
I would like to remind you that lemzoparlimab is differentiated by design to avoid binding to red blood cells while maintaining strong antitumor activity. This differentiation includes the expected favorable safety profile with no priming dose required, less RBC-mediated sink effect, and compelling antitumor activity across several. This molecular differentiation has been validated pre-clinically and has translated into clinical advantages that are being validated.
I should also add, in September 2022, AbbVie and I-Mab entered into an amendment to the original license and collaboration agreement. As a result, both parties are continuing to collaborate on the global development of anti-CD47 antibody therapy. Here I want to highlight lemzoparlimab safety differentiation with clinical data. In a systemic safety data review of approximately 200 patients who were treated with lemzoparlimab, either as monotherapy or in various combinations, we have seen a compelling safety profile to date.
Overall, the safety data from both the U.S. and China studies continued to be favorable when administered without a priming dose regimen. MTD was not reached in any dose regimen, mild TRAE in solid tumor and NHL, and we have seen a good safety profile in combination with azacitidine in AML and MDS, and no grade five hematological TRAEs have been reported.
In the phase II study in the MDS, we have observed a favorable safety profile shown on the right. Of note, this study enrolled more patients with worse baseline conditions than the comparable clinical trials conducted in Western countries due to the underlying disease that is heavily influenced by clinical practice in China. In this group, 74% of patients had grade three and above anemia and 61% of the patients had grade three and above thrombocytopenia at baseline.
The overall safety results showed that lemzoparlimab, even without the priming dose, was well-tolerated in combination with azacitidine, and the safety profile was comparable with that of azacitidine monotherapy. Next, I would like to highlight the clinical efficacy results presented at ESMO 2022. Of the 53 patients enrolled as of March 31st, 2022, for patients who began treatment six months or longer prior to the analysis, the overall response rate and complete response rate were 86.7% and 40%, respectively. For those who began treatment four months or longer, the ORR was 86.2% with a CRR of 31%.
I'm happy to share that the updated results from the most recent data analysis of 62 patients have demonstrated consistent clinical efficacy, including ORR and CRR, with no new safety signals identified. We are planning to present the updated data at a major scientific meeting in the second half in 2023.
Here, I would like to summarize the key progress on lemzoparlimab. We have observed consistent and favorable safety profiles in more than 200 patients with hematologic and solid tumors treated with lemzoparlimab. Our phase II MDS trial demonstrated a consistent efficacy trend, including ORR and CR, with a longer follow-up time since the ASCO data presentation in September 2022. Lemzoparlimab, in combination with azacitidine, has obtained approval from the CDE to initiate a phase III registration trial for the first-line treatment for patients with newly diagnosed higher risk MDS.
Importantly, AbbVie and I-Mab entered into an amendment to the original licensing collaboration agreement. As a result, both parties are continuing to collaborate on the global development of anti-CD47 antibody therapy. Next, I like to turn to uliledlimab, another global frontrunner that we are developing with a focus on non-small cell lung cancer.
As previously reported, uliledlimab is differentiated by design to avoid the hook effect. What is the hook effect? Simply put, the hook effect is characterized by an abnormal phenomenon that a drug molecule paradoxically loses the effect at higher dosage. As shown in the figure on the right side, uliledlimab achieved complete enzymatic inhibition without the hook effect. In contrast, atezolizumab could only achieve partial inhibition with hook effect with higher concentrations. Uliledlimab's differentiation comes from a unique binding epitope at the C-terminus.
We believe the differentiation gives uliledlimab the potential to be best in class with an improved therapeutic window and more flexibility when combined with other antitumor drugs. We have observed robust efficacy data in stage IV non-small cell lung cancer with high CD73 expression. We are currently focusing our efforts on a biomarker-guided phase II trial in advanced non-small cell lung cancer in the second half of 2023.
Shown on the left side of this slide is our PK study. It really demonstrated linear PK profiles at 5 mg /kg weekly or higher, indicating target saturation. At 30 mg/kg , saturation and complete inhibition of CD73 activity were observed in human tumor biopsy samples. Studies of uliledlimab in combination with an anti-PD-1 or PD-L1 have shown treatment is safe and well-tolerated, with no dose-limiting toxicities observed.
Most treatment-related adverse events were either grade one or grade two. Uliledlimab RP2D has been determined to be 30 mg /kg every three weeks in combination with toripalimab at 240 mg every three weeks. This slide highlights the clinical experience of our U.S. phase I study of uliledlimab in combination with atezolizumab in patients with refractory solid tumors.
Among 13 efficacy evaluable patients, three responses were seen, including one PR, with an overall response rate at 23% and a disease control rate at 46%. More importantly, shown on the right, all three responders were identified to exhibit higher expression of tumor 73, CD73, as compared to non-responders. This provides the initial indication that high CD73 expression may correlate with the clinical activity of uliledlimab. Here, I want to highlight the latest clinical development update on uliledlimab.
As of December 2022, 70 patients have been enrolled in the phase II study of uliledlimab in combination with toripalimab, a PD-1 antibody, in stage IV non-small cell lung cancer patients. As a high level of summary, at the time of the first data cutoff in March 2022, ORR was 26% and the DCR was 74% for the first 19 evaluable patients. Remarkably, in patients with high CD73 expression, defined of at least 35% expression level in tumor cells or immune cells. A much higher ORR was observed with a 57% ORR and DCR at 100%.
Similar efficacy data in relation to CD73 expression were obtained in August 2022 with 32 evaluable patients and December 2022 with 45 evaluable patients, showing a consistent trend of efficacy signal with an overall ORR greater than 30% in all patients and an ORR approximately 50% in CD73 high expression patients, as compared to approximately 10%-15% for those with CD73 low expression.
The efficacy data continued to mature for ORR and PFS in 2023. Our data have demonstrated that higher clinical response of uliledlimab and PD-1 combination therapy correlated with high tumor CD73 expression in patients with advanced non-small cell lung cancer. I want to summarize the key development of uliledlimab on this slide. Uliledlimab is a differentiated CD73 antibody with best-in-class potential. It can achieve complete CD73 inhibition without the hook effect.
Uliledlimab has a favorable safety profile, and the combination of uliledlimab plus pembrolizumab demonstrated robust antitumor activity in non-small cell lung cancer, with the clinical responses correlating with CD73 expression. With regard to our further development plan for uliledlimab, a data readout for the 70 patients in our phase II study is expected for ORR in the first half of 2023, and for PFS in the second half of 2023.
The company plans to present the data at a major scientific venue in 2023. A further clinical development plan is being finalized to include a biomarker-guided pivotal trial of uliledlimab in combination with PD-1 therapy in stage IV non-small cell lung cancer in second half of 2023 in China, and a global study of uliledlimab in combination with a PD-1 therapy and chemo regimen in advanced non-small cell lung cancer.
In parallel, a companion diagnostic kit is being developed with WuXi Diagnostics and is on track for the planned studies. With the new data, the company has been actively engaging in a potential global partnership in sync with the planned global study. The last asset I'd like to touch on today is givastomig, our novel Claudin 18.2/ 4-1BB bispecific antibody that has also made significant clinical progress.
Givastomig is a novel bispecific antibody with one arm targeting Claudin 18.2 and the other targeting 4-1BB through conditional or local activation. The key differentiation of givastomig is twofold. Firstly, it binds to tumor with a wide range of Claudin 18.2 expression levels, including lower expression, as demonstrated on the right in preclinical models.
Secondly, the 4-1BB arm of givastomig is designed to function upon local tumor engagement as a mechanism of conditional activation. This feature makes givastomig a unique T-cell activator only localized at the tumor site without systemic toxicities. For example, liver toxicity and systemic cytokine release that are typically associated with 4-1BB.
Here, I'd like to take a moment to highlight givastomig's unique differentiation compared to other Claudin 18.2 target agents. The differentiated molecular design makes givastomig unique among Claudin 18.2 target agents, including ADC and zolbetuximab, a Claudin 18.2 monoclonal antibody. Givastomig has the potential to target a broader population, including those with lower Claudin 18.2 expression. In contrast, the antitumor activity with zolbetuximab and ADC is rather limited to patients with higher Claudin 18.2 expression in the tumor.
Secondly, the 4-1BB arm of givastomig is designed to function upon local tumor engagement as a mechanism of conditional activation. This feature makes givastomig a unique T-cell activator with no systemic toxicities, including hepatic toxicity and cytokine release syndrome. Givastomig exhibits less gastrointestinal toxicity than that is commonly observed for other Claudin 18.2 targeted therapeutics.
Together, givastomig is clinically positioned to target gastric and pancreatic cancers that have lower Claudin 18.2 expression and are considered not eligible for treatment by zobi or Claudin ADC respectively. Those with high 18.2 expression by offering a more favorable safety profile over other Claudin 18.2 therapeutic modalities. Zobi has the potential to be combined with first-line standard chemo PD-1 therapy in gastric cancer and also in several other tumor types. The preliminary clinical data are consistent with the differentiation of givastomig.
Here I want to summarize the ongoing phase I dose escalation trial of givastomig in patients with advanced or metastatic solid tumors. By the end of 2022, eight dose cohorts have been completed up to 15 mg/kg without encountering dose-limiting toxicity. Most treatment-related adverse events are grade 1 or grade 2.
There is a dose-dependent increase of drug exposure and soluble 4-1BB in serum, suggestive of a favorable PK/PD profile and potentially a longer dosing interval with durable T-cell activation. At 5 mg/kg or above, C-trough reaches its target concentration in over 90% of the patients observed. Meanwhile, PD data indicate that TCR activation occurs only at tumor site.
As mentioned, we have disclosed a PR at 5 mg /kg last July, and we have since seen additional single-agent efficacy signal, including PR and stable disease in different cohorts as well. We expect to share the phase I data in the second half of 2023, and we continue to engage in discussions for a potential global partnership.
Finally, I would like to highlight the expected catalyst in the near future. The first area is really to deliver our pre-BLA assets. We expect a phase III data readout on eftansomatropin alfa in the second half of 2023, followed by subsequent BLA submission. We are particularly excited about this asset and the market opportunity that exists in China. We're also on track with phase III for felzartamab and a potential commercial partnership. The second area is on the clinical development of lemzoparlimab.
We will initiate the phase III clinical trial for lemzoparlimab as a first-line MDS treatment. We expect our phase III study in China will support a planned BLA submission with the goal of being first to market and first in class in China. Next is uliledlimab, our exciting CD73 antibody. This year, we expect an additional data readout for uliledlimab phase II non-small cell lung cancer trial, while planning to initiate a biomarker-guided pivotal study in stage IV non-small cell lung cancer in the second half of 2023. We continue to engage in discussions for a potential global partnership.
Finally, we continue to be excited by the development we see in givastomig. We are currently completing our phase I clinical trial and continue to engage in discussion for a potential partnership. Lastly, we expect to initiate new INDs this year.
As a reminder, I have not even touched on the multiple preclinical-stage assets we have in development. The company continues to focus on fundamentals with innovative strategies. With that, I'm happy to turn over to Richard, who will discuss our financials. Richard.
Thank you, Andrew. Let me turn to review our financial results for the full year ended December 31st, 2022. As of December 31st, 2022, our cash and cash equivalents and short-term investments were RMB 3.5 billion or $514 million. Compared with RMB 4.3 billion or $671 million as of December 31st, 2021. I-Mab's strong cash balance is expected to provide the company with adequate funding to support key business operations over the next three years. Total revenue for the full year of 2022 were RMB -221.6 million or $32.1 million, compared with the RMB 88 million for the full year of 2021.
The decrease in 2022 net revenue was primarily due to an one-off accounting treatment of $48 million, recorded in the second half 2022, following the amendment to the original license and collaboration agreement with AbbVie in August 2022. Further details can be found in our annual financial results. The decrease was partially offset by the revenue of RMB 92.6 million or $13.4 million from license and collaboration arrangements and the supply of pipeline products.
Let me turn to the R&D expenses. Research and development expenses for the full year of 2022 were RMB 904.9 million or $131 million, compared with RMB 1.2 billion for the full year of 2021.
The decrease was primarily due to the reduced demand for pipeline products as the company prepared to procure the sufficient stock for the pipeline products in 2021 and a lower share-based compensation expenses. Administrative expenses for the full year of 2022 were RMB 720 million or $104.4 million, compared with RMB 800 million, RMB 899 million for the full year of 2021. The decrease was primarily due to lower share-based compensation expenses in relation to the management personnel and an optimized control of operation and administrative expenses.
Net other expenses for the full year of 2022 were RMB 126.6 million or $18.4 million, compared with net other income of RMB 83.2 million for the full year of 2021. The change was primarily caused by unrealized exchange losses due to fluctuation in exchange rate of RMB against the U.S. dollars in 2022. I would like to reiterate that we maintain a strong cash position of $514 million that we held at the end of 2022. Our current cash position, combined with potential upcoming milestone payments from the previous out-licensing deals and the collaborations, is expected to further strengthen our cash reserves.
This has been largely achieved by our move to focus on five key clinical assets in our pipeline through our reprioritization effort in mid-2022. We also streamlined our corporate structure. This has also been included in streamline our workforce through a headcount optimization that was in line with the reprioritization of our pipeline, reducing our overall operating expenses in the corporate structure.
With this, we have implemented cost initiatives that we intend to maintain committed to as we were determined to maintain operational efficiency and a very lean operational budget. Overall, this represents about a 20% reduction in cost in 2022. We're expected to further reduce in 2023 as we continue to focus on where we can deliver the most important value to our shareholders.
In closing, our current strong cash position will provide us with ample flexibility to support our R&D activities in the next three years. With that, I would now like to turn the call back to Tyler and begin our Q&A sessions. Tyler?
Thank you, Richard. Thank you, Dr. Zhu, for your time and for your insights today. Next, we will begin our Q&A session. If you do have any questions, please use Zoom's raise your hand feature, and we'll unmute you for your questions. First question we see is from Kelly Shi. Kelly, please go ahead.
Thank you, Tyler, and thank you for taking my questions. My first question is, has I-Mab being able to resolve its delisting risks fully? I also have follow-up. Thanks.
Yeah. Hey, hey, Kelly. Thank you for your question. I think most of the delisting risk has been mitigated by our work with our current auditor through the PCAOB new rules. Our delisting risk has been largely mitigated throughout last year.
Thanks. Also regarding the phase II trial of CD73 antibody in stage IV non-small cell lung cancer, your updated 70 patients has been enrolled by the end of last year. I'm curious, could you share more information regarding the patient baseline characteristics regarding PD-L1 expression level and also prior PD-1 treatment? Are they like a refractory or relapsed as from any other PD-1 agents? Thank you.
Yeah. Let me take that question. Kelly, as I indicated in my presentation, the data that I presented, the one with 70 patient cohort. That's specifically targeting the treatment naive stage four non-small cell lung cancer. They are definitely naive to all the treatments, including PD-1. Okay. Yeah.
Sorry, go ahead.
Do you have a follow-up question?
Oh, no. Sorry, go ahead. I'm okay.
Yeah. Basically, I think in our study, exclusively looked at that particular population, you know, for our activity and also tolerability in our phase II trial.
Okay, thank you.
Thank you, Kelly. I'm showing Joe Catanzaro. Joe, please go ahead.
Hey, guys. Hopefully you can hear me okay. Maybe just one quick one from me on givastomig. I know you touched on this a bit in the prepared remarks, but the Claudin 18.2 space has obviously become highly competitive. Maybe for two questions around this. First, how do you think about the data that we've seen for zolbetuximab and the implications around Claudin 18.2 as a target? Then second, given the competitiveness with a lot of different modalities, how do you think givastomig is positioned here? Thanks.
Joe, great question. I think, you know, with the data from SPOTLIGHT and GLOW, you know, two phase III trials in the first line, metastatic gastric cancer space. With the addition of zobi to the standard chemo backbone, both studies, you know, convincingly demonstrated the improved benefit. I think, you know, clearly, we have validated Claudin being a relevant therapeutic target in gastric cancer. I think that part, you know, I personally feel that, you know, there's actually no argument. I think anti Claudin 18.2 antibody has a role. You know, this will, you know, definitely benefit patients with metastatic gastric cancer.
Also, as you know, both trials select patients based on Claudin 18.2 expression, and the criteria they use, is actually 2+ plus 3+ of at least 75%. You can imagine, you know, I think if you, if you look at this population very carefully, this probably will be applicable for about 30% of the patient with high Claudin expression, Claudin 18.2 expression. My feeling is that, you know, I think zobi will have the role in certain patients. And also, for those, you know, who have low PD-L1 expression, this may become the major, target therapy in combination with chemo.
Having said that, you know, we also feel strongly that givastomig has a very, very unique position, in a very crowded, you know, Claudin 18.2 therapeutic target space, in gastric and potentially maybe in other tumor types. Because, you know, the unique molecular design, really allow this molecule to cover a wider population, with different levels of Claudin 18.2 expression, in particular, the lower, 18.2 expression. We demonstrated that in preclinical models, you know, clearly it behaves favorably, with more robust antitumor activity, in comparison, with other Claudin 18.2 target antibody.
Our ongoing phase I trial also give us the initial confidence that, you know, we definitely have seen antitumor activity in Claudin 18.2 low expression patients, granted that our trial is still actually just ongoing. It's a phase I study. Nevertheless, we are encouraged by the early efficacy signal. On the other side of the spectrum, is really the safety profile with our unique molecular design. As I indicated in my presentation, our molecule will only become active when the molecule is engaged with the tumor-associated antigen, in this case, Claudin 18.2 positive tumor cells. In this case, the 4-1BB will get activated. In this way, it actually spares the systemic toxicity, including hepatic and also cytokine release syndrome.
This is actually commonly seen, you know, with other T-cell invader modalities, including 4-1BB base. So we think, you know, our molecule also has the added advantage, even for those with high Claudin 18.2 population, because it may potentially have the potential to be combined with the standard first line, you know, for example, FOLFIRINOX PD-1 based combo.
Also for other tumor types, we definitely have the potential to explore the combination of our drug with other combination chemotherapy in other tumor types. Lastly, as you know, there is actually the so-called class-specific side effects associated with Claudin 18.2 target agents, because the GI toxicity is actually very remarkable. You know, nausea and vomiting is commonly observed. Some of them, you know, could be actually incredibly challenging to manage.
In our trial, we only observe very mild gastrointestinal toxicity, in particular nausea and vomiting, which we think, you know, offers the advantage to be better tolerated, you know, in gastric cancer patients. We definitely would like to further explore, you know, givastomig development, either as a single agent, as we're doing right now, but also in combination down the road. Thank you, Joe.
Thank you, Dr. Zhu, and thank you, Joe, for that question. Next, we'll have Louise Chen. Louise?
Hi. Thanks for taking my question. Do you have any concerns regarding the toxicity of 4-1BB agonists? These features have prevented high target engagement in past programs. Can we expect more results from this dose escalation study? Thank you.
Yeah. I think, Louise, I will take your question. Yeah. Again, it's a very, very important question when it comes to the tolerability, the safety of any bispecific antibody, particularly comes to the T-cell engager modality. I think, you know, as I was trying to answer to Joe's question earlier, I did mention that our bispecific design is unique in a sense that we can only induce 4-1BB activation upon Claudin 18.2 engagement at the tumor site. For this reason, we actually spare the systemic toxicity commonly associated with 4-1BB and also other agonist treatment.
In that sense, you know, the toxicity concern associated with other 4-1BB antibody or actually other T-cell engager, including CD3 base, definitely, we actually have a very favorable safety profile as shown in our phase I ongoing phase I trial. Because, you know, we're not actually seeing the systemic toxicity, including cytokine toxicity, cytokine release syndrome. Also the added bonus for our bispecific is that, you know, our GI toxicity also is on the mild side.
Thank you, Dr. Zhu. Thank you, Louise, for that question. I will take one last question since we're a bit over time. Andres Maldonado. Andres, please go ahead.
Hi, guys. Thanks for taking my question. quick one from me. could you provide additional color on how we should be thinking about your expected cash burn rate in 2023? A quick follow-up to that is, obviously, you've been focusing on the four highlighted programs from your prepared remarks. Just curious from a timing-wise and a financial perspective, where do you expect to feel comfortable bringing in additional assets to the clinic in the future? Thank you.
Thank you for the question, Joe. Let me start with the financial, you know, the burn rate question, and Andrew can answer the pipeline question. With this regard, as we have mentioned, that in 2022, we actually spent a lot of time actually optimizing our cost structure. First of all, we actually focus on the five key assets, and second, really optimizing the organizational structure. This year we're further gonna reduce the overall cost, as we just mentioned in the call, that are expected of the current net burn rate for 2023, is expected to be in the range of $130 million-$140 million.
This will further optimize our operational structure so that our cash position can retain us at least for additional three years of, or more years of, cash operation. Given that we have other pipeline products that Andrew will discuss to develop, and we really focus our key assets. Yeah. I think, Andres, this is a very, very important question for the R&D operation. I think a few things that I would like to share with you. As you know, that I-Mab actually has a very, very innovative discovery engine. We actually produce quite a lot of innovative assets internally.
Also for reasons that we discussed today, we've been actually really trying to focus on the key assets that we can actually generate more value, you know, move the program to the next level faster, also realize the value of these assets hopefully earlier, so that, you know, the company will benefit, the shareholders will benefit, but more importantly, patients will benefit from this strategy.
Having said that, we never stop looking at innovative assets from outside. It's just, you know, right now with the current situation, our bar is higher. You know, we definitely want to take a more critical look when it comes to, you know, the licensing efforts from outside. This, you know, this is a dynamic process.
You know, clearly, we are aiming to also generate additional capital with our BD deal. I think clearly, you know, we will reassess, you know, the strategy as we, you know, proceed with the new year in 2023. but right now, you know, we definitely want to make sure we focus on the internal assets, but definitely we will actually look at the key assets that potentially have value and also have potential market more critically. you know, this is our current position.
Thank you, Dr. Zhu, and thank you, Richard. With that, we will conclude today's call. I'd like to thank you all for dialing in to today's financial results and business update conference call. Yeah, thanks, everyone, for joining and you may now disconnect.